New product
Availability date:
Brand | Exbio |
Product type | Primary antibodies |
Reactivity | Human |
Clonality | Monoclonal |
Brand: | Exbio |
Product no.: | 11-299-C025 |
Product type: | Primary antibodies |
Host species: | Mouse |
Product name: | Mouse Monoclonal to CD25 / IL-2R alpha chain |
Antigen: | CD25 |
Clonality: | Monoclonal |
Clone: | MEM-140 |
Isotype: | IgM |
Immunogen: | PHA-activated peripheral blood leucocytes |
Format: | purified |
Specificity: | The antibody MEM-140 reacts with CD25 (Interleukin-2 receptor alpha chain), a 55 kDa type I transmembrane glycoprotein expressed on activated B and T lymphocytes, activated monocytes/macrophages and on CD4+ T lymphocytes (T regulatory cells); it is lost on resting B and T lymphocytes. HLDA VI; WS Code C C-54 |
Categories: | CD and Related Antigens (Human) |
Concentration: | 1 mg/ml |
Storage buffer: | Tris buffered saline (TBS) with 15 mM sodium azide, approx. pH 8.0 |
Storage / stability: | Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on vial label. |
Background: | CD25 (IL2Ralpha, Tac) is a ligand-binding alpha subunit of interleukin 2 receptor (IL2R). Together with beta and gamma subunit CD25 constitues the high affinity IL2R, whereas CD25 alone serves as the low affinity IL2R. CD25 expression rapidly increases upon T cell activation. The 55 kDa CD25 molecule is enzymatically cleaved and shed from the cell surface as a soluble 45 kDa s-Tac, whose concentration in serum can be used as a marker of T cell activation. Expression of CD25 indicates the neoplastic phenotype of mast cells. Humanized anti CD25 antibodies represent a useful tool to reduce the incidence of allograft rejection as well as the severity of graft versus host reaction, and radioimmunoconjugates of anti-CD25 antibodies can be used against CD25 expressing lymphomas. |
Purity: | > 95% (by SDS-PAGE) |
Purification: | Purified by precipitation and chromatography |
Product specific references: | *Leukocyte Typing VI., Kishimoto T. et al. (Eds.), Garland Publishing Inc. (1997). |
General references: | *Sotlar K, Horny HP, Simonitsch I, Krokowski M, Aichberger KJ, Mayerhofer M, Printz D, Fritsch G, Valent P: CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. Am J Surg Pathol. 2004 Oct;28(10):1319-25._x000D_ _x000D_ _x000D_ , *Morris JC, Waldmann TA: Advances in interleukin 2 receptor targeted treatment. Ann Rheum Dis. 2000 Nov;59 Suppl 1:i109-14._x000D_ _x000D_ _x000D_ , *Scheibenbogen C, Keilholz U, Richter M, Andreesen R, Hunstein W: The interleukin-2 receptor in human monocytes and macrophages: regulation of_x000D_ expression and release of the alpha and beta chains (p55 and p75). Res Immunol. 1992 Jan;143(1):33-7._x000D_ _x000D_ _x000D_ , *Lai KN, Leung JC, Lai FM: Soluble interleukin 2 receptor release, interleukin 2 production, and interleukin_x000D_ 2 receptor expression in activated T-lymphocytes in vitro._x000D_ Pathology. 1991 Jul;23(3):224-8._x000D_ _x000D_ |
Related products: | - Mouse Monoclonal to CD26 - Mouse Monoclonal to CD253 / TRAIL - Mouse Monoclonal to CD255 / TWEAK |
Shipping condition: | Room temperature |